BLAINTRAMUSCULARVIAL
Approved
Dec 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
7
Data completeness
4/8 — Partial
MYOBLOC (rimabotulinumtoxinb) by Design Pharmaceuticals is acetylcholine release inhibitors [moa]. First approved in 2000.
Drug data last refreshed 8h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MYOBLOC (rimabotulinumtoxinB) is a botulinum toxin type B product approved in 2000 that works by inhibiting acetylcholine release at the neuromuscular junction. It is administered intramuscularly as a vial injection and is used to treat conditions involving involuntary muscle contractions.
$0.915MPart D
LOE ApproachingProduct is in late-stage lifecycle with minimal Part D penetration, suggesting a mature, stable commercial team focused on retention rather than growth initiatives.
Mechanism of Action
Acetylcholine Release Inhibitors
Pharmacologic Class:
Acetylcholine Release Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (7)
Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity
Started Nov 2021
32 enrolled
SpasticityCerebrovascular AccidentMultiple Sclerosis+3 more
Efficacy and Safety Study of MYOBLOC in the Treatment of Sialorrhea in Pediatric Subjects
Started Nov 2021
0Sialorrhea
Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Lower Limb Spasticity
Started Dec 2019
40 enrolled
Spasticity
Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adults
Started Oct 2015
187 enrolled
Sialorrhea
Efficacy and Safety Study of MYOBLOC® in the Treatment of Sialorrhea in Adult Subjects
Started Nov 2013
187 enrolled
Sialorrhea
Worked on MYOBLOC at Design Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.